ATE303793T1 - Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes - Google Patents
Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffesInfo
- Publication number
- ATE303793T1 ATE303793T1 AT02713167T AT02713167T ATE303793T1 AT E303793 T1 ATE303793 T1 AT E303793T1 AT 02713167 T AT02713167 T AT 02713167T AT 02713167 T AT02713167 T AT 02713167T AT E303793 T1 ATE303793 T1 AT E303793T1
- Authority
- AT
- Austria
- Prior art keywords
- active ingredient
- pharmaceutical composition
- therapeutically active
- core
- prolonged
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000005923 long-lasting effect Effects 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000012528 membrane Substances 0.000 abstract 3
- 229920000642 polymer Polymers 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 239000004014 plasticizer Substances 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN96DE2001 | 2001-01-30 | ||
| PCT/IN2002/000062 WO2003063825A1 (en) | 2001-01-30 | 2002-03-22 | Pharmaceutical composition for extended/sustained release of therapeutically active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE303793T1 true ATE303793T1 (de) | 2005-09-15 |
Family
ID=27638221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02713167T ATE303793T1 (de) | 2001-01-30 | 2002-03-22 | Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20030175349A1 (de) |
| EP (1) | EP1469824B1 (de) |
| JP (1) | JP2006508891A (de) |
| KR (1) | KR100878882B1 (de) |
| CN (1) | CN1301706C (de) |
| AT (1) | ATE303793T1 (de) |
| DE (1) | DE60206078T2 (de) |
| ES (1) | ES2248529T3 (de) |
| WO (1) | WO2003063825A1 (de) |
| ZA (1) | ZA200406112B (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| CA2467490C (en) | 2001-11-30 | 2007-01-09 | Pfizer Products Inc. | Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene |
| US20060188568A1 (en) * | 2003-10-30 | 2006-08-24 | Lupin Limited | Stable formulations of ace inhibitors and methods for preparation thereof |
| EP1916994B1 (de) * | 2004-06-29 | 2013-12-11 | Takeda Pharma A/S | Herstellung einer pharmazeutischen zusammensetzung mit schneller freisetzung aus wasserunlöslichen arzneimitteln und mit dem erfindungsgemässen verfahren erhaltene pharmazeutische zusammensetzungen |
| AU2005266459A1 (en) * | 2004-07-29 | 2006-02-02 | Sanofi-Aventis | Pharmaceutical multilayer tablet for controlled release of active ingredients with highly pH-dependent solubility |
| US20070077297A1 (en) | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| EP1896002A4 (de) * | 2005-06-27 | 2009-11-25 | Biovail Lab Int Srl | Bupropionsalzformulierungen mit modifizierter freisetzung |
| EP1951266A2 (de) | 2005-09-02 | 2008-08-06 | Genzyme Corporation | Verfahren zur entfernung von phosphat und dafür verwendetes polymer |
| PT1924246E (pt) | 2005-09-15 | 2016-02-10 | Genzyme Corp | Formulação sachê para polímeros com funcionalidade amina |
| US7709014B2 (en) * | 2005-10-17 | 2010-05-04 | Yu Ruey J | Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites |
| KR100702069B1 (ko) * | 2005-10-31 | 2007-03-30 | (주)이엘티사이언스 | 파라세타몰 경구용 수용산제 복합조성물 및 그 제조방법 |
| DK1976509T3 (en) * | 2006-01-18 | 2015-03-23 | Evolva Sa | PPAR modulators |
| EP2012757A2 (de) * | 2006-04-24 | 2009-01-14 | Pfizer Products Incorporated | Asymmetrische membrane für arzneiabgabevorrichtungen |
| US20070269492A1 (en) * | 2006-05-16 | 2007-11-22 | Per Steen | New product and use and manufacture thereof |
| WO2008042222A2 (en) | 2006-09-29 | 2008-04-10 | Genzyme Corporation | Amide dendrimer compositions |
| US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
| US7749537B2 (en) | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
| EP2120972A1 (de) | 2006-12-14 | 2009-11-25 | Genzyme Corporation | Amido-amin-polymerzusammensetzungen |
| US20090004281A1 (en) * | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
| EP2224913B1 (de) | 2007-12-04 | 2014-10-15 | Remedy Pharmaceuticals, Inc. | Verbesserte formulierungen und verfahren zur lyophilisierung und damit bereitgestellte lyophilisate |
| WO2009097443A2 (en) | 2008-01-29 | 2009-08-06 | Remedy Pharmaceuticals, Inc. | Liquid formulations of compounds active at sulfonylurea receptors |
| CN101259113B (zh) * | 2008-04-21 | 2013-02-13 | 沈阳药科大学 | 依托度酸渗透泵型控释制剂 |
| EP2228066A1 (de) * | 2009-03-03 | 2010-09-15 | LEK Pharmaceuticals d.d. | Pharmazeutische Zusammensetzungen eines auf Sulphonylharnstoff basierenden pharmazeutischen Wirkstoffs mit ausgezeichneten Auflösungseigenschaften |
| CN101618027B (zh) * | 2009-07-16 | 2013-07-31 | 沈阳药科大学 | 醋氯芬酸双层渗透泵控释片及其制备方法 |
| JP5600174B2 (ja) * | 2009-09-15 | 2014-10-01 | チーム アカデミー オブ ファーマシューティカル サイエンス | 浸透圧ポンプ型放出制御錠及びその製造方法 |
| CN102670575A (zh) * | 2011-03-09 | 2012-09-19 | 中国药科大学 | 酮洛芬渗透泵型控释制剂及其制备方法 |
| CN102133205B (zh) * | 2011-03-17 | 2013-12-11 | 山东新华制药股份有限公司 | 一种格列吡嗪渗透泵控释片的制备方法 |
| SI2760821T1 (en) * | 2011-09-02 | 2018-02-28 | Novartis Ag | A salt salt of an anti-inflammatory substituted cyclobutenedione compound |
| CN103142565B (zh) * | 2012-04-18 | 2015-04-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种尼美舒利的缓释药物组合物及其制备方法 |
| DK2659881T3 (en) * | 2012-04-30 | 2018-02-05 | Tillotts Pharma Ag | Delayed release drug formulation |
| WO2014060952A1 (en) * | 2012-10-16 | 2014-04-24 | Ranbaxy Laboratories Limited | Osmotic floating tablets |
| CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
| DE102015122319A1 (de) * | 2015-12-18 | 2017-06-22 | Special Coatings Gmbh & Co. Kg | Trommelbeschichtungsverfahren und -vorrichtung für kleine mengen an zu beschichtenden kleinteilen |
| GB2546513B (en) * | 2016-01-20 | 2020-09-16 | Cubic Pharmaceuticals Ltd | Process of preparing active pharmaceutical ingredient salts |
| CN105581993B (zh) * | 2016-03-11 | 2018-06-29 | 常州欧法玛制药技术有限公司 | 一种阿司匹林渗透泵控释片及其制备方法 |
| CN109303765A (zh) * | 2018-11-21 | 2019-02-05 | 南京泽恒医药技术开发有限公司 | 一种呋塞米口服溶液及其制备方法 |
| EP4057989A1 (de) * | 2019-11-14 | 2022-09-21 | Pfizer Inc. | 1-(((2s,3s,4s)-3-ethyl-4-fluor-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisochinolin-6-carboxamid kombinationen und orale dosierungsformen |
| CA3210407A1 (en) * | 2021-03-04 | 2022-09-09 | Kenny K. Tran | Low-sorbing glyburide formulation and methods |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1468172A (en) * | 1973-03-28 | 1977-03-23 | Benzon As Alfred | Oral drug preparations |
| US4160452A (en) * | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| DE2831164A1 (de) * | 1978-07-15 | 1980-01-24 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| GB8616669D0 (en) * | 1986-07-09 | 1986-08-13 | Merk Sharpe & Dohme Ltd | Pharmaceutical compositions |
| US4880631A (en) * | 1987-09-24 | 1989-11-14 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| NZ226179A (en) * | 1987-09-24 | 1991-04-26 | Merck & Co Inc | Controlled porosity osmotic pump for sustained release of pharmaceutical agents |
| JPH0791184B2 (ja) * | 1988-03-31 | 1995-10-04 | 田辺製薬株式会社 | 放出制御型製剤およびその製法 |
| US5612059A (en) * | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IL91398A (en) * | 1988-08-30 | 1994-05-30 | Pfizer | Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane |
| SE9202250D0 (sv) * | 1992-07-29 | 1992-07-29 | Gacell Lab Ab | Controlled release morphine preparation |
| TW235239B (de) * | 1992-11-20 | 1994-12-01 | Pfizer | |
| JP4072597B2 (ja) * | 1994-12-27 | 2008-04-09 | ナムローゼ・フェンノートシャップ・オルガノン | 持続性製剤 |
| US5736159A (en) * | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
| US5654005A (en) * | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
| GB9620709D0 (en) * | 1996-10-04 | 1996-11-20 | Danbiosyst Uk | Colonic delivery of weak acid drugs |
| US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| AU1444301A (en) * | 1999-10-29 | 2001-05-14 | Merck & Co., Inc. | Osmotic controlled release drug delivery device |
| SE0001151D0 (sv) * | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
-
2002
- 2002-03-20 US US10/101,237 patent/US20030175349A1/en not_active Abandoned
- 2002-03-22 DE DE60206078T patent/DE60206078T2/de not_active Expired - Lifetime
- 2002-03-22 ES ES02713167T patent/ES2248529T3/es not_active Expired - Lifetime
- 2002-03-22 AT AT02713167T patent/ATE303793T1/de active
- 2002-03-22 CN CNB028286693A patent/CN1301706C/zh not_active Expired - Lifetime
- 2002-03-22 EP EP02713167A patent/EP1469824B1/de not_active Expired - Lifetime
- 2002-03-22 JP JP2003563519A patent/JP2006508891A/ja active Pending
- 2002-03-22 KR KR1020047012012A patent/KR100878882B1/ko not_active Expired - Lifetime
- 2002-03-22 WO PCT/IN2002/000062 patent/WO2003063825A1/en not_active Ceased
-
2004
- 2004-07-30 ZA ZA200406112A patent/ZA200406112B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1301706C (zh) | 2007-02-28 |
| EP1469824B1 (de) | 2005-09-07 |
| KR100878882B1 (ko) | 2009-01-15 |
| CN1622799A (zh) | 2005-06-01 |
| WO2003063825A1 (en) | 2003-08-07 |
| EP1469824A1 (de) | 2004-10-27 |
| ES2248529T3 (es) | 2006-03-16 |
| DE60206078D1 (de) | 2005-10-13 |
| KR20040091006A (ko) | 2004-10-27 |
| DE60206078T2 (de) | 2006-07-13 |
| JP2006508891A (ja) | 2006-03-16 |
| US20030175349A1 (en) | 2003-09-18 |
| ZA200406112B (en) | 2006-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE303793T1 (de) | Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes | |
| HRP20090209T1 (hr) | Proizvodnja uređaja za dugotrajno oslobađanje lijeka sa polimerima na bazi poliuretana | |
| HRP20100682T1 (hr) | Formulacija tablete produljenog oslobadanja koja sadrzi pramipeksol ili njegovu farmaceutski prihvatljivu sol, postupak njezine priprave i uporaba | |
| CY1110264T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν ευαισθητα σε ρη συμπολυμερη τυπου μπλοκ και υδροφοβο φαρμακο | |
| NL2000281A1 (nl) | Vaste farmaceutische samenstellingen die pregabaline bevatten. | |
| WO2007036952A3 (en) | Novel sustained release dosage form | |
| DE60036534D1 (de) | Feste pharmazeutische formulierungen auf basis von sulfoalkylethern des cyclodextrins zur verzögerten freisetzung | |
| DE69917866D1 (de) | Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe | |
| IS6863A (is) | Ný himnuhúð | |
| WO2007000778A3 (en) | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof | |
| DE502007003020D1 (de) | Wirkstoffpartikelhaltiges transdermales therapeutisches system mit erhöhtem wirkstofffluss | |
| ATE286387T1 (de) | Clarithromycin enthaltende zubereitung mit verlängerter freisetzung | |
| ATE358160T1 (de) | Ph-responsive biologisch abbaubare polymilchsäurederivate, die polymermicellen bilden, und deren verwendung zur zufuhr von schlecht wasserlöslichen arzneistoffen | |
| BG108516A (en) | Pharmaceutical formulation | |
| ATE406870T1 (de) | Filmförmige, zerfallsfähige zubereitungen zur wirkstoff-freisetzung und verfahren zu deren herstellung | |
| ATE361060T1 (de) | Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung | |
| ATE464878T1 (de) | Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl | |
| WO2009072334A1 (ja) | 製剤用核粒子 | |
| CY1108551T1 (el) | Ελεγχομενης απελευθερωσης συνθεσεις της βεταϊστινης | |
| EA200300110A1 (ru) | Композиция элетриптана в виде частиц | |
| JP2005526061A5 (de) | ||
| MX2009003815A (es) | Formulaciones farmaceuticas. | |
| NO20025461L (no) | Nye formuleringer av <alfa>-(2,4-disulfofenyl)-N-tert- butylnitron | |
| ATE245974T1 (de) | Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung | |
| JP2002537246A5 (de) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1469824 Country of ref document: EP |